The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Cancer Stem Cells and Drug Resistance: The Potential of Nanomedicine
Open accessAbstract
Properties of the small group of cancer cells called tumor-initiating or cancer stem cells (CSCs) involved in drug resistance, metastasis and relapse of cancers can significantly affect tumor therapy. Importantly, tumor drug resistance seems to be closely related to many intrinsic or acquired properties of CSCs, such as quiescence, specific morphology, DNA repair ability and overexpression of antiapoptotic proteins, drug efflux transporters and detoxifying enzymes. The specific microenvironment (niche) and hypoxic stability provide additional protection against anticancer therapy for CSCs. Thus, CSC-focused therapy is destined to form the core of any effective anticancer strategy. Nanomedicine has great potential in the development of CSC-targeting drugs, controlled drug delivery and release, and the design of novel gene-specific drugs and diagnostic modalities. This review is focused on tumor drug resistance-related properties of CSCs and describes current nanomedicine approaches, which could form the basis of novel combination therapies for eliminating metastatic and CSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,389
Targeted drug delivery to tumors: Myths, reality and possibility
Bae, Y. H., & Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.001 · Cited by 1,935
The stem-cell niche as an entity of action
Scadden, D. T. (2006) · Nature · doi:10.1038/nature04957 · Cited by 1,856
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., Maira, G., Parati, E. A., Stassi, G., Larocca, L. M., et al. (2010) · Nature · doi:10.1038/nature09557 · Cited by 1,379
Grange, C., Tapparo, M., Collino, F., Vitillo, L., Damasco, C., Deregibus, M. C., Tetta, C., Bussolati, B., & Camussi, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0241 · Cited by 851
Wang, Z., Li, Y., Kong, D., Banerjee, S., Ahmad, A., Azmi, A. S., Ali, S., Abbruzzese, J. L., Gallick, G. E., & Sarkar, F. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4312 · Cited by 619
Self-assembled hyaluronic acid nanoparticles for active tumor targeting
Choi, K. Y., Chung, H., Min, K. H., Yoon, H. Y., Kim, K., Park, J. H., Kwon, I. C., & Jeong, S. Y. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.030 · Cited by 578
ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma
Frank, N. Y., Margaryan, A., Huang, Y., Schatton, T., Waaga-Gasser, A. M., Gasser, M., Sayegh, M. H., Sadee, W., & Frank, M. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3327 · Cited by 574
Pharmacological Strategies for Overcoming Multidrug Resistance
Nobili, S., Landini, I., Giglioni, B., & Mini, E. (2006) · Current Drug Targets · doi:10.2174/138945006777709593 · Cited by 393
Folkins, C., Man, S., Xu, P., Shaked, Y., Hicklin, D. J., & Kerbel, R. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4238 · Cited by 385
Patil, Y., Sadhukha, T., Ma, L., & Panyam, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.01.021 · Cited by 317
Upadhyay, K. K., Bhatt, A. N., Mishra, A. K., Dwarakanath, B. S., Jain, S., Schatz, C., Le Meins, J.-F., Farooque, A., Chandraiah, G., Jain, A. K., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.12.043 · Cited by 316
Patil, Y. B., Swaminathan, S. K., Sadhukha, T., Ma, L., & Panyam, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.048 · Cited by 304
Hovinga, K. E., Shimizu, F., Wang, R., Panagiotakos, G., Van Der Heijden, M., Moayedpardazi, H., Correia, A. S., Soulet, D., Major, T., Menon, J., et al. (2010) · Stem Cells · doi:10.1002/stem.429 · Cited by 302
CD44‐positive cells are responsible for gemcitabine resistance in pancreatic cancer cells
Hong, S. P., Wen, J., Bang, S., Park, S., & Song, S. Y. (2009) · International Journal of Cancer · doi:10.1002/ijc.24573 · Cited by 290
Khdair, A., Chen, D., Patil, Y., Ma, L., Dou, Q. P., Shekhar, M. P. V., & Panyam, J. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.004 · Cited by 275
Aldehyde Dehydrogenase as a Marker for Stem Cells
Moreb, J. (2008) · Current Stem Cell Research & Therapy · doi:10.2174/157488808786734006 · Cited by 272
Wnt/β-catenin signaling regulates cancer stem cells in lung cancer A549 cells
Teng, Y., Wang, X., Wang, Y., & Ma, D. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.028 · Cited by 250
Nucleoside analogs: molecular mechanisms signaling cell death
Ewald, B., Sampath, D., & Plunkett, W. (2008) · Oncogene · doi:10.1038/onc.2008.316 · Cited by 247
Li, R., Wu, R., Zhao, L., Wu, M., Yang, L., & Zou, H. (2010) · ACS Nano · doi:10.1021/nn9011225 · Cited by 245
Wu, W., Shen, J., Banerjee, P., & Zhou, S. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.06.030 · Cited by 236
Lim, K. J., Bisht, S., Bar, E. E., Maitra, A., & Eberhart, C. G. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.5.14410 · Cited by 232
Mamaeva, V., Rosenholm, J. M., Bate-Eya, L. T., Bergman, L., Peuhu, E., Duchanoy, A., Fortelius, L. E., Landor, S., Toivola, D. M., Lindén, M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.105 · Cited by 220
Chen, Y., Bathula, S. R., Li, J., & Huang, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.125906 · Cited by 216
Looking ahead in cancer stem cell research
Dick, J. E. (2009) · Nature Biotechnology · doi:10.1038/nbt0109-44 · Cited by 211
Rausch, V., Liu, L., Kallifatidis, G., Baumann, B., Mattern, J., Gladkich, J., Wirth, T., Schemmer, P., Büchler, M. W., Zöller, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0066 · Cited by 209
Is Tumor Growth Sustained by Rare Cancer Stem Cells or Dominant Clones?
Adams, J. M., & Strasser, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6334 · Cited by 204
Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Wilson, T., Johnston, P., & Longley, D. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166547 · Cited by 203
Wang, C.-H., Chiou, S.-H., Chou, C.-P., Chen, Y.-C., Huang, Y.-J., & Peng, C.-A. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2010.06.010 · Cited by 194
Barth, B. M., I. Altinoğlu, E., Shanmugavelandy, S. S., Kaiser, J. M., Crespo-Gonzalez, D., DiVittore, N. A., McGovern, C., Goff, T. M., Keasey, N. R., Adair, J. H., et al. (2011) · ACS Nano · doi:10.1021/nn2005766 · Cited by 178
Identification and targeting of cancer stem cells
Schatton, T., Frank, N. Y., & Frank, M. H. (2009) · BioEssays · doi:10.1002/bies.200900058 · Cited by 174
Kim, T.-H., Mount, C. W., Gombotz, W. R., & Pun, S. H. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.06.004 · Cited by 164
Milane, L., Duan, Z., & Amiji, M. (2011) · Molecular Pharmaceutics · doi:10.1021/mp1002653 · Cited by 161
Glazer, E. S., Zhu, C., Massey, K. L., Thompson, C. S., Kaluarachchi, W. D., Hamir, A. N., & Curley, S. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2055 · Cited by 161
Yao, H.-J., Ju, R.-J., Wang, X., Zhang, Y., Li, R., Yu, Y., Zhang, L., & Lü, W.-L. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.038 · Cited by 151
Honoki (2010) · Oncology Reports · doi:10.3892/or_00000885 · Cited by 151
Chen, H., Li, H., Li, J., Zhu, Z. G., Yin, S., Hao, X., Yao, M., Zheng, S.-S., & Gu, J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn223 · Cited by 146
Significance of HIF-1-active cells in angiogenesis and radioresistance
Harada, H., Kizaka‐Kondoh, S., Li, G., Itasaka, S., Shibuya, K., Inoue, M., & Hiraoka, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210556 · Cited by 145
Mimeault, M., & Batra, S. K. (2011) · Chinese Medicine · doi:10.1186/1749-8546-6-31 · Cited by 144
Zhang, L., Yao, H.-J., Yu, Y., Zhang, Y., Li, R., Ju, R.-J., Wang, X., Sun, M., Shi, J., & Lü, W.-L. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.055 · Cited by 129
Expression of Multidrug Resistance Genes in Normal and Cancer Stem Cells
Shervington, A. A., & Lu, C. (2008) · Cancer Investigation · doi:10.1080/07357900801904140 · Cited by 129
Milane, L. S., Ganesh, S., Shah, S., Duan, Z., & Amiji, M. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.03.032 · Cited by 128
Water-dispersible multifunctional hybrid nanogels for combined curcumin and photothermal therapy
Wu, W., Shen, J., Banerjee, P., & Zhou, S. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.08.112 · Cited by 127
Kato, T., Natsume, A., Toda, H., Iwamizu, H., Sugita, T., Hachisu, R., Watanabe, R., Yuki, K., Motomura, K., Bankiewicz, K. S., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.88 · Cited by 127
Liu, C., Zhao, G., Liu, J., Ma, N., Chivukula, P., Perelman, L. A., Okada, K., Chen, Z., Gough, D., & Yu, L. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.08.013 · Cited by 127
Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells
Kobune, M., Takimoto, R., Murase, K., Iyama, S., Sato, T., Kikuchi, S., Kawano, Y., Miyanishi, K., Sato, Y., Niitsu, Y., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01111.x · Cited by 126
Li, R.-J., Ying, X., Zhang, Y., Ju, R.-J., Wang, X.-X., Yao, H.-J., Men, Y., Tian, W., Yu, Y., Zhang, L., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.019 · Cited by 119
Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer
Verma, A. K., Guha, S., Diagaradjane, P., Kunnumakkara, A. B., Sanguino, A. M., Lopez‐Berestein, G., Sood, A. K., Aggarwal, B. B., Krishnan, S., Gelovani, J. G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4529 · Cited by 101
Pulsed Ultrasound Enhances Nanoparticle Penetration into Breast Cancer Spheroids
Grainger, S. J., Serna, J. V., Sunny, S., Zhou, Y., Deng, C. X., & ElSayed, M. E. H. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100280b · Cited by 99
Schwartz, D. L., Bankson, J. A., Lemos, R., Lai, S. Y., Thittai, A. K., He, Y., Hostetter, G. H., Demeure, M. J., Hoff, D. D. V., & Powis, G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0768 · Cited by 97
Banzato, A., Bobisse, S., Rondina, M. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2019 · Cited by 92
Characterization of primary ovarian cancer cells in different culture systems
Lai (2010) · Oncology Reports · doi:10.3892/or_00000761 · Cited by 62
Jin, F., Zhao, L., Guo, Y.-J., Zhao, W.-J., Zhang, H., Wang, H.-T., Shao, T., Zhang, S., Wei, Y., Feng, J., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.04.005 · Cited by 60
Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133
Bourseau-Guilmain, E., Bejaud, J., Griveau, A., Lautram, N., Hindré, F., Weyland, M., Benoît, J., & Garcion, E. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.06.001 · Cited by 57
Hypoxia protects HepG2 cells against etoposide-induced apoptosis VIA a HIF-1-independent pathway
Piret, J., Cosse, J.-P., Ninane, N., Raes, M. J., & Michiels, C. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.05.018 · Cited by 56
Rochat, B. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909789056999 · Cited by 54
Wirthner, R., Wrann, S., Balamurugan, K., Wenger, R. H., & Stiehl, D. P. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn231 · Cited by 51
Ambardekar, V. V., Han, H.-Y., Varney, M. L., Vinogradov, S. V., Singh, R. K., & Vetro, J. A. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.019 · Cited by 43
Self-citationZhou, P., Hatziieremia, S., Elliott, M. A., Scobie, L., Crossan, C., Michie, A. M., Holyoake, T. L., Halbert, G., & Jørgensen, H. G. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.09.016 · Cited by 34
Tumor-targeted RNA-interference: functional non-viral nanovectors.
Pan, X., Thompson, R., Meng, X., Wu, D., & Xu, L. (2011) · PubMed · Cited by 30
Zhang, H., Gerson, T., Varney, M. L., Singh, R. K., & Vinogradov, S. V. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0256-x · Cited by 29
Self-citationGalmarini, C. M., Warren, G., Senanayake, M. T., & Vinogradov, S. V. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.05.028 · Cited by 28
Self-citationHIF-1α modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines
Choi, Y. J., Rho, J. K., Lee, S. J., Jang, W. S., Lee, S. S., Kim, C. H., & Lee, J. C. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0543-2 · Cited by 25
Maturation of tumor vasculature by interferon-beta disrupts the vascular niche of glioma stem cells.
Williams, R. F., Sims, T. L., Tracey, L., Myers, A. L., Ng, C. Y., Poppleton, H., Nathwani, A. C., & Davidoff, A. M. (2010) · PubMed · Cited by 20
Cited by
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733
“Further, tumor microenvironment can create hypoxic situations in which tumor tissue has a diminished oxygen supply that can contribute to MDR [69].”
BackgroundPlant-derived anticancer agents: A green anticancer approach
Iqbal, J., Abbasi, B. A., Mahmood, T., Kanwal, S., Ali, B., Shah, S. A., & Khalil, A. T. (2017) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2017.10.016 · Cited by 685
He, Q., & Shi, J. (2014) · Advanced Materials · doi:10.1002/adma.201303123 · Cited by 482
Targeting non-coding RNAs to overcome cancer therapy resistance
Chen, B., Dragomir, M. P., Yang, C., Li, Q., Horst, D., & Calin, G. A. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00975-3 · Cited by 435
Point of care testing: The impact of nanotechnology
Syedmoradi, L., Daneshpour, M., Alvandipour, M., Gomez, F. A., Hajghassem, H., & Omidfar, K. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.08.084 · Cited by 367
Metadata
- Authors
- Vinogradov, S., & Wei, X.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2012-04
- Volume
- 7
- Issue
- 4
- Pages
- 597-615
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2129883523
- Cited by
- 474
- References
- 64
- FWCI
- 11.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.